Zejula Indications Food

facebook share image   twitter share image   pinterest share image   E-Mail share image

More about "zejula indications food"

ZEJULA: PACKAGE INSERT / PRESCRIBING INFORMATION - DRUGS.COM

From drugs.com
6.5/10 (51)
Published Mar 27, 2017
Estimated Reading Time 8 mins


PR ZEJULA - PDF.HRES.CA
Web Indications (1.1) 10/2020 Recommended Dose and Dosage Adjustment, Recommended Dosage (4.2) 10/2020 ... ZEJULA may be taken with or without food. Bedtime …
From pdf.hres.ca
File Size 663KB
Page Count 45


HIGHLIGHTS OF PRESCRIBING INFORMATION CONTINUE …
Web ZEJULA is a poly(ADP-ribose) polymerase (PARP) inhibitor indicated: for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary …
From accessdata.fda.gov
File Size 922KB
Page Count 31


ZEJULA PRODUCT MONOGRAPH - GSK
Web ZEJULA (niraparib capsules and tablets) is indicated: as monotherapy for the maintenance treatment of female adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based …
From ca.gsk.com
File Size 565KB
Page Count 47


ZEJULA (NIRAPARIB CAPSULES): USES, DOSAGE, SIDE EFFECTS ... - RXLIST
Web Dec 20, 2022 Indications & Dosage INDICATIONS First-Line Maintenance Treatment Of Advanced Ovarian Cancer ZEJULA is indicated for the maintenance treatment of adult …
From rxlist.com


NIRAPARIB (ZEJULA) | CANCER INFORMATION | CANCER RESEARCH UK
Web Mar 31, 2023 Niraparib (Zejula) Niraparib is a type of targeted cancer drug called a PARP inhibitor. It is also known as Zejula. ... Avoiding fatty or fried foods, eating small meals …
From cancerresearchuk.org


ZEJULA (NIRAPARIB) CAPSULES - GSKPRO
Web ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: • for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, …
From gskpro.com


SEARCH ORPHAN DRUG DESIGNATIONS AND APPROVALS - FOOD AND DRUG ...
Web Apr 30, 2010 Generic Name: niraparib. Trade Name: Zejula. Marketing Approval Date: 03/27/2017. Approved Labeled Indication: Indicated for maintenance treatment of adult …
From accessdata.fda.gov


GSK ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL OF …
Web Oct 23, 2019 GSK Announces U.S. FDA Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer Contacts …
From businesswire.com


PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION …
Web Withhold ZEJULA for a maximum of 28 days and monitor blood counts weekly until platelet counts return to H í ì ì, ì ì ì/µL. Resume ZEJULA at same or reduced dose per Table 1. If …
From pdf.hres.ca


GSK PROVIDES AN UPDATE ON ZEJULA (NIRAPARIB) US …
Web Nov 11, 2022 GSK plc (LSE/NYSE: GSK) today provided an update that at the request of the US Food and Drug Administration (FDA) it will restrict the second-line maintenance …
From gsk.com


ZEJULA (NIRAPARIB) DOSING, INDICATIONS, INTERACTIONS, ADVERSE …
Web Withhold up to 28 days and monitor blood cell counts weekly until neutrophils ≥1500/mcL or hemoglobin ≥9 g/dL; resume at reduced dose. Discontinue if neutrophils and/or …
From reference.medscape.com


ZEJULA: USES, DOSAGE, SIDE EFFECTS, WARNINGS - DRUGS.COM
Web Aug 25, 2022 Zejula is used as a maintenance treatment to keep certain types of cancer from coming back. This includes ovarian cancer, fallopian tube cancer, or peritoneal …
From drugs.com


NIRAPARIB (ZEJULA) | FDA - U.S. FOOD AND DRUG …
Web On March 27, 2017 , the U.S. Food and Drug Administration approved niraparib (ZEJULA, Tesaro, Inc.), a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance …
From fda.gov


| CANCER CARE ONTARIO
Web Jun 1, 2022 Niraparib should be taken with or without food at approximately the same time each day. (Bedtime administration may help manage nausea). Capsule should be …
From cancercareontario.ca


ZEJULA | EUROPEAN MEDICINES AGENCY
Web Feb 13, 2023 Therapeutic indication Zejula is indicated: as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and …
From ema.europa.eu


ZEJULA (NIRAPARIB) CAPSULES` - FOOD AND DRUG ADMINISTRATION
Web indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the …
From accessdata.fda.gov


TREATMENT OPTION FOR OVARIAN CANCER | ZEJULA (NIRAPARIB)
Web Pain in the stomach area Mouth sores Diarrhea Indigestion or heartburn Dry mouth Tiredness Loss of appetite Urinary tract infection Changes in liver function or other blood …
From zejula.com


ZEJULA: SIDE EFFECTS, DOSAGE, ALTERNATIVES, AND MORE - MEDICAL NEWS …
Web Jul 8, 2020 Mild side effects of Zejula can include:* nausea and vomiting fatigue (lack of energy) constipation belly pain muscle pain decreased appetite trouble sleeping …
From medicalnewstoday.com


LABEL - ACCESSDATA.FDA.GOV
Web (2.1) • ZEJULA may be taken with or without food. (2. 1) • For adverse reactions, consider interruption of treatment, dose reduction, or dose discontinuation. (2.2) • For patients with …
From accessdata.fda.gov


ZEJULA (NIRAPARIB) - SIDE EFFECTS, INTERACTIONS, USES, DOSAGE, WARNINGS
Web Jul 31, 2020 Zejula (Niraparib) Generic Name: Niraparib Reviewed: July 31, 2020 Niraparib is used as a "maintenance" treatment in adults to keep certain types of cancer …
From everydayhealth.com


FDA APPROVES NIRAPARIB FOR FIRST-LINE MAINTENANCE OF ADVANCED …
Web On April 29, 2020, the Food and Drug Administration approved niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced …
From fda.gov


THE CLIMATE CRISIS IS UPENDING INDIA’S FOOD ECONOMY
Web 14 hours ago Apr 28, 2023 12:19 PM IST. Read this news in brief form. The recent zoom in the cost of cumin is more than a price hike problem. It's an indication of impending …
From hindustantimes.com


REFERENCE ID: 4075456 - FOOD AND DRUG ADMINISTRATION
Web ZEJULA may be taken with or without food. Bedtime administration may be a potential method for managing nausea. Patients should start treatment with ZEJULA no later than …
From accessdata.fda.gov


Related Search